Repare Therapeutics (RPTX) Announces Leadership Transitions

Repare Therapeutics Inc. (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that Steve Forte, Executive Vice President and Chief Financial Officer, has been appointed as President and Chief Executive Officer and to the Board of Directors effective April 11, 2025. He will serve in this new role in addition to his current role as the Company’s Chief Financial Officer. Lloyd M. Segal has resigned as President, Chief Executive Officer and as a member of the Board of Directors effective April 11, 2025, in order to pursue other opportunities. Additionally, Sandra Alves, Vice President and Corporate Controller, has been promoted to Chief Accounting Officer.

Steve Forte brings more than 20 years of finance and biotech leadership experience to the CEO role. Mr. Forte joined Repare Therapeutics in 2019 as Executive Vice President and Chief Financial Officer. He played a critical role in Repare’s successful initial public and secondary offerings, and has a deep knowledge of the Company’s core business and operations. Prior to joining Repare, Mr. Forte served as Chief Financial Officer of Clementia Pharmaceuticals, a leading innovator in treatments for rare diseases, during which Clementia was acquired by Ipsen S.A. for $1.3 billion.

“Steve has been integral to all aspects of Repare’s strategy, business development, financings and operations since assuming the role of Chief Financial Officer in 2019, and has fostered strong relationships across our industry and with the Repare Therapeutics team,” said Thomas Civik, Chairman of the Board of Directors. “We are confident in Steve’s ability to create value for shareholders and continue to deliver on key data catalysts in 2025.”

Mr. Civik continued, “We thank Lloyd for over eight years of leadership and impact at Repare, starting as a co-founder in 2016, guiding the company through its IPO, building a world-class team and developing innovative clinical programs. Lloyd recently led the Company through a restructuring to position Repare most effectively to meet the important new challenges ahead. We wish him all the best in his future endeavors.”

Following its recent re-alignment of resources and re-prioritization of its clinical portfolio, Repare is focused on the advancement of three ongoing Phase 1 clinical trials. Repare expects to complete enrollment of the MYTHIC trial evaluating lunresertib (RP-6306) in combination with Debio 0123 (WEE1 Inhibitor) in Q2 2025. Topline safety, tolerability and early efficacy data from the Phase 1 POLAR clinical trial of RP-3467 is expected in Q3 2025. Initial topline safety, tolerability and early efficacy data from the Phase 1 LIONS clinical trial of RP-1664 and in combination with olaparib is expected in Q4 2025. The Company is also exploring strategic alternatives and partnerships across its portfolio, including for lunresertib and camonsertib.

You May Also Be Interested In

• Pizza Hut CEO Aaron Powell resigns
• Albany International ends strategic review, keeps Salt Lake City facility
• United Community Banks completes $2B Navitas sale to Wafra